GSK receives marketing authorisation from the European Commission for additional indication: Tyverb™ (lapatinib) in combination with trastuzumab for patients with HER2-positive, HR-negative metastatic breast cancer
14 August 2013 | By GlaxoSmithKline
“Today’s announcement is important for women with this specific type of metastatic breast cancer..."